Computational model of EGFR and IGF1R pathways in lung cancer

By Supriya Bidanta1; FNU POORVA2; Dhanusha Duraiyan3

1. Indiana University, Bloomington 2. Indiana University Bloomington 3. Indiana university bloomington

A Computational model of EGFR and IGF1R pathways in lung cancer

Launch Tool

You must login before you can run this tool.

Version 1.0 - published on 06 Dec 2022

doi:10.21981/Q676-Q139 cite this

Open source: license | download

View All Supporting Documents

Category

Tools

Published on

Abstract

Lung cancer has been a prolonged issue in our life. In order to understand the biology beneath the cause, it is important to understand the minute details of it.

This application is built in order to understand the  molecular biology of the Epidermal
Growth Factor Receptor (EGFR, also known as ErbB1/HER1) and type 1 Insulin-like Growth Factor (IGF1R)
pathways in non-small cell lung cancer (NSCLC) using system biology approach. The model is based on ordinary differential equations, of the pathways and study the dynamic implications of receptor
alterations on the time behavior of the MAPK cascade down to ERK, which in turn governs proliferation and
cell migration.

The application educates about the EGFR and IGF1R interaction along the process of activating ERK pathway. Nonetheless, there are other pathways that plays a role in tumor cell proliferation, we pre-dominantly focus in ERK pathway.

EGFR - IGFR Pathway

References

  1. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic pi3k deregulates transcription and translation.Nat Rev Cancer 2005;5(12):921–9.
  1. Becker MA, Yee D. Egfr signaling networks in cancer therapy (chapter 11). Business2008:155–68.
  1. Bianconi F, Baldelli E, Ludovini V, Crinò L, Flacco A, Valigi P. Computational model of EGFR and IGF1R pathways in lung cancer: a Systems Biology approach for Translational Oncology. Biotechnol Adv. 2012 Jan-Feb;30(1):142-53. doi: 10.1016/j.biotechadv.2011.05.010. Epub 2011 May 18. Erratum in: Biotechnol Adv. 2013 Mar-Apr;31(2):358-60. PMID: 21620944.
  1. Bianconi F. Dynamic modeling, parameter estimation and experiment design in Systems Biology with applications to Oncology. Ph.D. thesis. University of Perugia;2010.
  1. Bianconi F, Lillacci G, Valigi P. Dynamic modeling and parameter identification for biological networks: application to the DNA damage and repair processes. In: Liu LA, Wei D, Li Y, editors. Handbook of research on computational and systems biology: interdisciplinary applications; 2010.
  1. Blakesley V, Stannard B, Kalebic T, et al. Role of the IGF-I receptor in mutagenesis and tumor promotion. J Endocrinol 1997;152:339–44.
  1. Boguski M, McCormick F. Proteins regulating ras and its relatives. Nature 1993;366(6456):643–54.
  1. Brown KS, Hill CC, Calero Ga, Myers CR, Lee KH, Sethna JP, et al. The statistical mechanics of complex signaling networks: nerve growth factor signaling. Physical Biology 2004;1(3–4):184–95.
  1. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ERBB-2 and erbb-3. Experimental Cell Research 2003;284(1):54–65.
  1. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine & Growth Factor reviews 2005;16(4–5):421–39.
  1. Dong Chen, Waters SB, Holt KH, Pessin JE. Sos phosphorylation and disassociation of the grb2–sos complex by the erk and jnk signaling pathways. The Journal of biological chemistry 1996;271(11):6328–32.
  1. Dufourny B, Alblas J, vanTeeffelen H, et al. Mitogenic signaling of insulin-like growth factor i in mcf-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997;272:31163–71.
  1. Dziadziuszko R, Merrick D, Witta S, Mendoza A, Szostakiewicz B, Szymanowska A, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between igf1r fluorescent in situ hybridization, protein expression, and mrna expression. J Clin Onco 2010;28(13):2174–80
  1. Gary L, Johnson RL. Mitogen-activated protein kinase pathways mediated by erk, jnk, and p38 protein kinases. Science 2002;298(5600):1911–2.
  1. Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, et al. High expression levels of total igf-1r and sensitivity of nsclc cells in vitro to an anti-igf-1r antibody (r1507). PloS one 2009;4(10):e7273.
  1. Gonzalez-Angulo AM, Hennessy BTJ, Mills GB. Future of personalized medicine in oncology: A systems biology approach. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010;28(16):2777–83.
  1. Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang Y, Hixon M, et al. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor i receptor inhibition. Clin Cancer Res 2010;16(18):4654–65.
  1. Guan KL, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD, et al. Negative regulation of the serine/threonine kinase b-raf by akt. The Journal of Biological Chemistry 2000;275 (35):27354–9.
  1. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the pi3k/akt pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4(12):988-1004.
  1. Hindmarsh AC, Brown PN, Grant KE, Lee SL, Serban R, Shumaker DE, et al. Sundials: suite of nonlinear and differential/algebraic equation solvers. ACM Trans Math Software 2005;31(3):363–96.
  1. Jiang Y, Rom WN, Yie Ta, Chi CX, Tchou-Wong KM. Induction of tumor suppression and glandular differentiation of a549 lung carcinoma cells by dominant-negative igf-i receptor. Oncogene 1999;18(44):6071–7.
  1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16(1):3-34.
  1. Khandwala H, McCutcheon I, Flyvbjerg A, Friend K. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215–44.
  1. Kim EK, Choi EJ. Pathological roles of mapk signaling pathways in human diseases. Biochimica et Biophysica Acta 2010;1802(4):396–405.
  1. Lazebnik Y. Can a biologist fix a radio? — or, what I learned while studying apoptosis.Cancer cell 2002;2(3):179–82.
  1. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor i receptor. Endocr Rev 1995;16(2):143–63.
  1. López-Calderero I, Chávez ES, García-Carbonero R. The insulin-like growth factor pathway as a target for cancer therapy. Clinical and Translational Oncology 2010;12(5):326–38.
  1. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni a, et al. High co-expression of both insulin-like growth factor receptor-1 (igfr-1) and epidermal growth factor receptor (egfr) is associated with shorter disease-free survival in resected nonsmall-cell lung cancer patients. Annals of Oncology: official Journal of the EuropeanSociety for Medical Oncology/ESMO 2009;20(5):842–9.

Cite this work

Researchers should cite this work as follows:

  • Supriya Bidanta, FNU POORVA, Dhanusha Duraiyan (2022), "Computational model of EGFR and IGF1R pathways in lung cancer," https://nanohub.org/resources/egfrigf1r. (DOI: 10.21981/Q676-Q139).

    BibTex | EndNote

Tags

  1. cancer
  2. education/outreach
  3. mathematical modeling
  4. systems biology